Ftse Mib
33.736,40
-0,03%
DAX
17.896,50
-0,14%
S&P 500
5.064,20
0,91%
NASDAQ
15.840,96
1,51%
Bitcoin
59.730,35
1,03%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ AnaptysBio Inc (ANAB) AnaptysBio Inc (ANAB) Notizie

AnaptysBio Inc

ANAB
26,34
0,32 (1,23%)
02 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/4/202415:00PRNUSActym Therapeutics Appoints Thomas Smart as CEO
11/3/202421:41EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/3/202421:36EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11/3/202421:19EDGAR2Form 8-K - Current report
29/2/202415:15GLOBEAnaptys to Present at TD Cowen’s 44th Annual Health Care..
14/2/202416:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202414:35EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202415:15GLOBEAnaptys to Present at Guggenheim’s 6th Annual Biotechnology..
10/1/202401:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202401:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:09EDGAR2Form 8-K - Current report
27/11/202322:17EDGAR2Form 8-K - Current report
27/11/202322:15GLOBEAnaptys Expands Immune Cell Modulator Pipeline with..
07/11/202322:15GLOBEAnaptys Named a BioSpace 2024 Best Places to Work Winner
02/11/202321:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202321:18EDGAR2Form 8-K - Current report
02/11/202321:15GLOBEAnaptys Announces Third Quarter 2023 Financial Results and..
01/11/202314:15GLOBEAnaptys Announces Participation in November Investor..
25/10/202322:43EDGAR2Form 8-K - Current report
11/10/202315:15GLOBEAnaptys to Present Phase 1 Data on ANB032, its BTLA Agonist..
10/10/202315:01EDGAR2Form 8-K - Current report
09/10/202314:43DJNAnaptys Sees Positive Trial Results for Imsidolimad..
09/10/202314:15GLOBEAnaptys to Provide Overview of Rosnilimab, a PD-1 Agonist,..
09/10/202314:00GLOBEAnaptys Announces Positive Top-Line Phase 3 Clinical Trial..
19/9/202300:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/9/202300:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/9/202300:09EDGAR2Form 3 - Initial statement of beneficial ownership of..
18/9/202322:18EDGAR2Form 8-K - Current report
18/9/202322:15GLOBEAnaptysBio Announces Appointment of John Orwin as Chairman..
12/9/202315:15GLOBEAnaptysBio to Present at the Stifel 2023 Immunology and..
07/8/202322:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202322:18EDGAR2Form 8-K - Current report
07/8/202322:15GLOBEAnaptysBio Announces Second Quarter 2023 Financial..
31/7/202320:27DJNAnaptysBio Shares Rise 11% After Jemperli Plus Chemotherapy..
31/7/202319:34GLOBEAnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI..
30/5/202322:15GLOBEAnaptysBio Announces Participation in Upcoming Investor..
11/5/202322:15GLOBEAnaptysBio Announces First Quarter 2023 Financial Results..
Apertura: 26,02 Min: 24,75 Max: 26,74
Chiusura: 26,02

La tua Cronologia

NASDAQ
ANAB
AnaptysBio
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network